It’s been a few years since Brexit, and pharmaceutical companies have been adapting their therapy development plans as regulatory guidelines for different regions get updated. Health technology assessments or HTAs remain one area where the divergence of reimbursement frameworks in the UK and European Union is expected to impact how and when new therapies become available in those regions.
In this month’s issue, we take a look at how market access following an evolving process to conduct HTAs is expected to change in the near future in the UK.
Also, in this issue, we tackle the sparse research landscape for treatments for prion diseases and whether all generic manufacturers can pivot to producing specialty and complex generics.
Read the latest issue of Pharma Technology Focus for all this and more news, insights, data and analysis from the pharmaceutical industry.
You can also subscribe here to receive email notifications when a new issue is available.